Core Viewpoint - The company, Hansai Aitai-B, is set to launch an initial public offering (IPO) from December 15 to December 18, 2025, aiming to raise approximately HKD 4.96 billion for the development of its core products and other business activities [1][2]. Group 1: IPO Details - The company plans to globally offer 18.321 million shares, with 10% allocated for Hong Kong and 90% for international sales, at a price range of HKD 28-32 per share [1]. - The shares are expected to commence trading on the Hong Kong Stock Exchange on December 23, 2025 [1]. Group 2: Company Overview - The company specializes in structural biology, translational medicine, and clinical development, having developed a product pipeline since 2016 that includes one core product and nine other candidates targeting oncology and autoimmune diseases [1]. Group 3: Product Pipeline - HX009 is a self-developed dual-function antibody fusion protein targeting PD-1/SIRPα, with Phase I clinical trials completed in Australia and China, and three ongoing clinical projects in China [1]. - HX301 is a multi-target kinase inhibitor that has completed Phase I clinical research and is currently in Phase II clinical trials in combination with temozolomide for treating glioblastoma [1]. - HX044 is a novel dual-function anti-CTLA-4 antibody SIRPα fusion protein, undergoing Phase I/IIa clinical studies in Australia and China for the treatment of advanced solid tumors [1]. Group 4: Use of Proceeds - The net proceeds from the global offering, estimated at approximately HKD 4.96 billion, will be allocated to the research and development of core products HX009, HX301, and HX044, as well as for commercialization, business development activities, working capital, and other general corporate purposes [2].
翰思艾泰-B招股 拟全球发售1832.1万股